Bayer’s Wheat Deal and Supreme Court Tailwind Are Both in Play – But on Different Timetables
Published on 07/18/2026 at 16:34 | Redaktion boerse-global.de
Bayer’s stock has more than doubled from its 2024 lows, but the rally is now caught between a looming court date in Missouri and a wheat-seed venture that won’t generate meaningful revenue until the 2040s. The Leverkusen-based group finds itself managing immediate legal and financial milestones while simultaneously planting the seeds of a far?future growth story.
Shares closed Friday at €48.06, up 72.29% over the past twelve months but down 4.34% on the week. The weekly decline reflects unease over the rescheduling of a key “fairness hearing” for the company’s $7.25 billion glyphosate class?action settlement. A Missouri court pushed the hearing from early July to August 19, 2026, a delay that suggests the final legal closure of the Roundup legacy is still a work in progress. At €53.86, the stock’s 52?week high from early July now sits 10.77% above current levels.
The setback comes despite a clear legal win for Bayer. The U.S. Supreme Court ruled 7?2 that state?level cancer?warning claims over glyphosate face significantly higher hurdles, a decision that JPMorgan described as a game?changer when it reiterated its “Overweight” rating and €50 target on July 17. Barclays went a step further, lifting its target to €60 on July 14, while Berenberg raised its view to €55 but stuck with “Hold,” citing improved prospects for a eventual breakup of the conglomerate. Jefferies remained the most cautious, holding at €46 with a “Hold” rating.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer has not waited for the courtroom drama to resolve before tackling its balance sheet. On July 10 it secured €3 billion in equity from Apollo Global Management, giving Apollo?managed funds a minority stake in a new entity that houses Bayer’s reversible long?acting contraceptive business. A week later, on July 17, the company completed a $5 billion U.S. dollar bond placement to refinance existing debt. Fitch Ratings acknowledged the moves but kept its “BBB” long?term issuer default rating with a negative outlook on July 13, pointing to high net debt and persistent cash?flow strains.
Amid these short?term pressures, Bayer is also laying groundwork for a product that will take years to reach the field. On July 15 it signed an exclusive license agreement with French seed group RAGT to develop hybrid wheat for Europe and North America. The collaboration, which builds on a partnership begun in 2021, targets yields roughly 10% higher than conventional varieties along with better tolerance to drought, heat, and disease. Market launch is slated for the early 2030s, with Bayer forecasting annual sales of up to €1 billion by the mid?2040s. In Europe the focus will be on winter wheat; in North America both winter and summer wheat are planned.
The timing gap between the legal?financial headlines and the agricultural bet is unusually wide. Bayer’s annualised volatility stands at 62%, and the stock trades 16.50% above its 50?day moving average, a sign that the technical rally is starting to look stretched. The RSI of 59.3 has not yet reached overbought territory, but the rapid run?up has already eaten into the gap to analyst targets.
Investors now have two clear near?term catalysts to watch. Bayer will release its first?half 2026 results on August 4, offering a fresh look at underlying earnings and cash flow. Twelve days later, the Missouri court will hold the rescheduled fairness hearing, a decision that could remove or prolong the biggest cloud over the stock. In the background, the hybrid?wheat project will continue to grind forward, a reminder that Bayer is trying to run a three?pace race – legal, financial, and strategic – all at once.
Ad
Bayer Stock: New Analysis - 18 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
